β-D-Ribofuranose 1-Acetate 2,3,5-Tribenzoate CAS 6974-32-9 Intende ≥99.0% (HPLC) Clofarabine Intermedia High Purity Featured Image

β-D-Ribofuranose 1-Acetate 2,3,5-Tribenzoate CAS 6974-32-9 Intende ≥99.0% (HPLC) Clofarabine Intermedia High Puritas

Description:

Nomen: β-D-Ribofuranose 1-Aetate 2,3,5-Tribenzoate

CAS: 6974-32-9

Aspectus: Alba vel Off-White Crystalline pulveris

Dic: ≥99.0% (HPLC)

Intermedia Clofarabine (CAS: 123318-82-1) in tractatione Puerorum cum Leukemia acuta Lymphoblastica (ALL)

Inquiry: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Commercial Supple Clofarabine Intermedia:
Clofarabine CAS: 123318-82-1
2-Deoxy-2-fluoro-1,3,5-tri-O-benzoyl-α-D-arabinofuranose CAS: 97614-43-2
β-D-Ribofuranose 1-Acetate 2,3,5-Tribenzoate CAS: 6974-32-9
1,3,5-Tri-O-benzoyl-D-Ribofuranose CAS: 22224-41-5
2,6-Dichloropurinum CAS: 5451-40-1

Chemical Properties:

Nomen chemicum	β-D-Ribofuranose 1-Acetate 2,3,5-Tribenzoate
Synonyma	1-O.
CAS Number	6974-32-9
CATTUS Number	RF-PI222
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C28H24O9
M. Pondus	504.49
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba vel Off-White Crystalline pulveris
Asssay / Analysis Methodo	≥99.0% (HPLC)
Liquescens punctum	126.0~133.0℃
Damnum in Siccatio	≤0.50%
Residere in Ignition	≤0.50%
Totalis immunditias	≤1.00%
Metalla gravis	≤20ppm
Test Standard	Enterprise Standard
Consuetudinem	Pharmaceuticum intermedium Clofarabini CAS: 123318-82-1

Sarcina & Repono:

sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, umore et peste infestatione.

commoda:

FAQ:

Applicatio:

β-D-Ribofuranose 1-Acetate 2,3,5-Tribenzoate (CAS 6974-32-9) intermedium est (Clofarabine CAS: 123318-82-1).Clofarabine (CAS: 123318-82-1) medicamenta nova est nucleoside purina anticancerorum primum feliciter enucleata a Top10 biopharmaceutica societas Foederatarum Americae-Genzyme Corporation cum nominibus artis "Clofarabine".Die 28 mensis Decembris anno 2004 cibus US et Administration medicamentis (FDA) calliditate usus est ad approbationem clofarabinae ad applicationem puerorum cum refractorio vel relapso leukemia lymphocytica acuta (ALL);Egregiam vim habet in curatione leukemia bene tolerantia, nec vagus adversae profectae.Administrari potest per intravene vel administrari vel oretenus administrari.Hoc medicamentum primum productum probatum est quod curatione filiorum leukemia plus decem annis dicata est.